Analysts have been eager to weigh in on the Healthcare sector with new ratings on Biogen Inc (BIIB), Blueprint Medicines (BPMC) and Acceleron Pharma (XLRN).
Biogen Inc (BIIB)
In a report released today, Matthew Harrison from Morgan Stanley maintained a Sell rating on Biogen Inc, with a price target of $212.00. The company’s shares closed last Monday at $225.42, close to its 52-week low of $215.78.
According to TipRanks.com, Harrison is a 4-star analyst with an average return of 4.3% and a 53.5% success rate. Harrison covers the Healthcare sector, focusing on stocks such as Biohaven Pharmaceutical Holding Co Ltd, Global Blood Therapeutics, and Fulcrum Therapeutics Inc.
Biogen Inc has an analyst consensus of Hold, with a price target consensus of $263.50.
See today’s analyst top recommended stocks >>
Blueprint Medicines (BPMC)
In a report released today, David Lebovitz from Morgan Stanley maintained a Buy rating on Blueprint Medicines, with a price target of $109.00. The company’s shares closed last Monday at $73.48.
According to TipRanks.com, Lebovitz is a 2-star analyst with an average return of 1.0% and a 33.3% success rate. Lebovitz covers the Healthcare sector, focusing on stocks such as Rhythm Pharmaceuticals Inc, Ionis Pharmaceuticals Inc, and Zealand Pharma A/S.
Blueprint Medicines has an analyst consensus of Strong Buy, with a price target consensus of $111.57, implying a 53.1% upside from current levels. In a report issued on October 3, H.C. Wainwright also initiated coverage with a Buy rating on the stock with a $100.00 price target.
Acceleron Pharma (XLRN)
Morgan Stanley analyst Jeffrey Hung maintained a Hold rating on Acceleron Pharma today and set a price target of $48.00. The company’s shares closed last Monday at $39.10, close to its 52-week low of $37.01.
According to TipRanks.com, Hung is a 3-star analyst with an average return of 5.8% and a 50.0% success rate. Hung covers the Healthcare sector, focusing on stocks such as Alder Biopharmaceuticals, Voyager Therapeutics Inc, and Prevail Therapeutics Inc.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Acceleron Pharma with a $59.50 average price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
